Compare AbCellera Biologics Inc (ABCL) vs Applied Materials, Inc. (AMAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Applied Materials, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Applied Materials, Inc. trades at $572 (market cap $440.25B). The key difference: Applied Materials, Inc. is far larger — about 187.3× AbCellera Biologics Inc's market cap, and Applied Materials, Inc. pays a 0.38% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AMAT | |
|---|---|---|
Market Cap | $2.35B | $440.25B |
Sector | Health | Technology |
52-Week High | $8.12 | $723.00 |
52-Week Low | $2.78 | $156.25 |
Enterprise Value | $1.99B | $439.28B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Applied Materials (AMAT) trades at $592.79, down 1.78% on the day, amid a broader bullish technical trend. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.86 surpassing the $2.68 estimate. Strong profitability is evident with a net income margin of 29.31% and ROE of 39.69%. Recent news highlights the company's positioning in the AI-driven semiconductor equipment boom, with the CEO calling it 'the greatest time in the history of our industry' (CNBC, 2026-05-28).
The outlook remains positive, supported by robust analyst sentiment (76.92% buy ratings) and a consensus price target of $622.57, offering potential upside. Key risks include high valuation multiples (P/E of 55.77) and dependence on sustained semiconductor capital expenditure cycles. The stock presents an opportunity for growth investors aligned with the AI infrastructure theme, but requires monitoring of execution and market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →
